Enterprise Ireland 'Big Ideas' - Ian Robertson Engram

Engram -- Derisking Neurology and Psychiatry Drug Development

Engram Translational Neurosciences offers a unique suite of services for the development of drug treatments for Alzheimer's disease and other neurological conditions. Engram has developed systems that integrate data from behavioural, neuropharmacological and neurophysiological preclinical studies with neuro-cognitive, biomarker and imaging in humans with healthy and illness-impaired mental function.

Central Nervous System (CNS) drug research and development is a complex, difficult and expensive process because there is an imperfect relationship between preclinical studies and the human clinical situation. Finding external markers of CNS activity which can be translated from the clinic to the laboratory and vice versa in a meaningful fashion to allow for the assessment of drug effects of brain function has been very difficult.

Engram is targeting pharmaceutical and biotechnology companies with R&D programs for treatment of psychiatric and neurological conditions with research capability that has been developed and honed over a period of years with major pharma partners. We have developed rapid, integrative pre-clinical and clinical evaluation methods for novel drug candidates directed at improving mental function that allow the following:
• Rapid acceleration of psychiatry and neurology drug development into the clinical pipeline.
• Methods that may be useful for stratifying patient populations or identifying groups that might benefit from early or preventative intervention.
• Benchmarking of novel therapies and targets with current therapies and with the scientific literature.


Presenter: Prof. Ian Robertson, Trinity College Dublin
Collaborator: Transpharmation

Category:

Science & Technology

Tags:

• Enterprise
• Ireland
• 'Big
• Ideas'
• Ian
• Robertson
• Engram